Kissei’s Tavneos setback is putting pressure on its growth plans. What could this mean for international suppliers and licensing partners? We examine the company’s pipeline, the importance of reliable evidence and how to approach Kissei with a credible Japan proposition.
Daiichi Sankyo has built one of the pharmaceutical industry’s most productive antibody-drug conjugate platforms. Enhertu has […]
Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to […]